Vascular endothelial growth factor and soluble intercellular adhesion molecule-1 in lung adenocarcinoma with malignant pleural effusion: Correlations with patient survival and pleural effusion control

Neoplasma

Volumn 59, Issue 4, 2012, Pages 433-439

  Qian, Q ^a   Zhan, P ^a   Sun, W K ^b   Zhang, Y ^a   Song, Y ^b   Yu, L K ^a  

^a NANJING CHEST HOSPITAL   (China)

^b JINLING HOSPITAL   (China)

Author keywords

Lung adenocarcinoma; Malignant pleural effusion; Soluble intercellular adhesion molecule 1; Survival; Vascular endothelial growth factor

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; VASCULOTROPIN; ICAM1 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT PLEURA EFFUSION; MIDDLE AGED; OUTCOME ASSESSMENT; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUBERCULOSIS; ADENOCARCINOMA; CASE CONTROL STUDY; COMPARATIVE STUDY; ISOLATION AND PURIFICATION; LUNG TUBERCULOSIS; LUNG TUMOR; METABOLISM; MORTALITY; MYCOBACTERIUM; PATHOLOGY; PLEURA EFFUSION; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SMOKING; SURVIVAL RATE;

ADENOCARCINOMA; AGED; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; LUNG NEOPLASMS; MALE; MYCOBACTERIUM; NEOPLASM STAGING; PLEURAL EFFUSION, MALIGNANT; PROGNOSIS; RISK FACTORS; ROC CURVE; SMOKING; SURVIVAL RATE; TUBERCULOSIS, PULMONARY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84864541321     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2012_056     Document Type: Article

References (33)

1. LIGHT RW Clinical practice. Pleural effusion. N Engl J Med 2002; 346: 1971-1977.
2. ANTUNES G, NEVILLE E, DUFFY J, ALI N BTS guidelines for the management of malignant pleural effusions. Thorax 2003; 58 Suppl 2: ii29-38. http://dx.doi.org/10.1136/thorax.58.suppl_2.ii29
3. SUGIURA S, ANDO Y, MINAMI H, ANDO M, SAKAI S et al. Prognostic value of pleural effusion in patients with nonsmall cell lung cancer. Clin Cancer Res 1997; 3: 47-50.
4. NAITO T, SATOH H, ISHIKAWA H, YAMASHITA YT, KAMMA H et al. Pleural effusion as a significant prognostic factor in non-small cell lung cancer. Anticancer Res 1997; 17: 4743-4746.
5. MACCHIARINI P, FONTANININ G, HARDIN MJ, SQUARTINI F, ANGELETTI CA Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet 1992; 340: 145-146. http://dx.doi.org/10.1016/0140-6736(92)93217-B
6. FERRARA N, KERBEL RS Angiogenesis as a therapeutic target. Nature 2005; 438: 967-974. http://dx.doi.org/10.1038/nature04483
7. YANO S, SHINOHARA H, HERBST RS, KUNIYASU H, BUCANA CD et al. Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am J Pathol 2000; 157: 1893-1903. http://dx.doi.org/10.1016/S0002-9440(10)64828-6
8. YANO S, HERBST RS, SHINOHARA H, KNIGHTON B, BUCANA CD et al. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin Cancer Res 2000; 6: 957-965.
9. GEARING AJ, NEWMAN W Circulating adhesion molecules in disease. Immunol Today 1993; 14: 506-512. http://dx.doi.org/10.1016/0167-5699(93)90267-O
10. VANDE STOLPE A, VANDE SAAG PT Intercellular adhesion molecule-1. J Mol Med 1996; 74: 13-33. http://dx.doi.org/10.1007/BF00202069
11. ALEXIOU D, KARAYIANNAKIA AJ, SYRIGOS KN, ZBAR A, KREMMYDA A et al. Serum levels of E-selectin, ICAM-1 and VCAM-1 in colorectal cancer patients: correlations with clinicopathological features, patient survival and tumour surgery. Eur J Cancer 2001; 37: 2392-2397. http://dx.doi.org/10.1016/S0959-8049(01)00318-5
12. VIAC J, VINCENT C, PALACIO S, SCHMITT D, CLAUDY A Tumour necrosis factor (TNF) soluble receptors in malignant melanoma: correlation with soluble ICAM-1 levels. Eur J Cancer 1996; 32A: 447-449. http://dx.doi.org/10.1016/0959-8049(95)00541-2
13. NAKATA B, HORI T, SUNAMI T, OGAWA Y, YASHIRO M et al. Clinical significance of serum soluble intercellular adhesion molecule 1 in gastric cancer. Clin Cancer Res 2000; 6: 1175-1179.
14. DOWLATI A, GRAY R, SANDLER AB, SCHILLER JH, JOHNSON DH Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study. Clin Cancer Res 2008; 14: 1407-1412. http://dx.doi.org/10.1158/1078-0432.CCR-07-1154
15. GHO YS, KLEINMAN HK, SOSNE G Angiogenic activity of human soluble intercellular adhesion molecule-1. Cancer Res 1999; 59: 5128-5132.
16. GHO YS, KIM PN, LI HC, ELKIN M, KLEINMAN HK Stimulation of tumor growth by human soluble intercellular adhesion molecule-1. Cancer Res 2001; 61: 4253-4257.
17. SU WC, LAI WW, CHEN HH, HSIUE TR, CHEN CW et al. Combined intrapleural and intravenous chemotherapy, and pulmonary irradiation, for treatment of patients with lung cancer presenting with malignant pleural effusion. A pilot study. Oncology 2003; 64: 18-24. http://dx.doi.org/10.1159/000066516
18. NERAGI-MIANDOAB S Malignant pleural effusion, current and evolving approaches for its diagnosis and management. Lung Cancer 2006; 54: 1-9. http://dx.doi.org/10.1016/j.lungcan.2006.04.016
19. HEFFNER JE Diagnosis and management of malignant pleural effusions. Respirology 2008; 13: 5-20.
20. MUSANI AI Treatment options for malignant pleural effusion. Curr Opin Pulm Med 2009; 15: 380-387. http://dx.doi.org/10.1097/MCP.0b013e32832c6a8a
21. PERNG RP, CHEN YM, WU MF, CHOU KC, LIN WC et al. Phase II trial of intrapleural paclitaxel injection for non-smallcell lung cancer patients with malignant pleural effusions. Respir Med 1998; 92: 473-479. http://dx.doi.org/10.1016/S0954-6111(98)90294-3
22. CHENG D, LEE YC, ROGERS JT, PERKETT EA, MOYERS JP et al. Vascular endothelial growth factor level correlates with transforming growth factor-beta isoform levels in pleural effusions. Chest 2000; 118: 1747-1753. http://dx.doi.org/10.1378/chest.118.6.1747
23. THICKETT DR, ARMSTRONG L, MILLAR AB Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions. Thorax 1999; 54: 707-710. http://dx.doi.org/10.1136/thx.54.8.707
24. CHENG D, RODRIGUEZ RM, PERKETT EA, ROGERS J, BIENVENU G et al. Vascular endothelial growth factor in pleural fluid. Chest 1999; 116: 760-765. http://dx.doi.org/10.1378/chest.116.3.760
25. VERHEUL HM, HOEKMAN K, JORNA AS, SMIT EF, PINEDO HM Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. Oncologist 2000; 5 Suppl 1: 45-50. http://dx.doi.org/10.1634/theoncologist.5-suppl_1-45
26. STRIZZI L, CATALANO A, VIANALE G, ORECCHIA S, CASALINI A et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001; 193: 468-475. http://dx.doi.org/10.1002/path.824
27. ZEBROWSKI BK, YANO S, LIU W, SHAHEEN RM, HICKLIN DJ et al. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res 1999; 5: 3364-3368.
28. MASKELL NA, LEE YC, GLEESON FV, HEDLEY EL, PENGELLY G et al. Randomized trials describing lung inflammation after pleurodesis with talc of varying particle size. Am J Respir Crit Care Med 2004; 170: 377-382. http://dx.doi.org/10.1164/rccm.200311-1579OC
29. BURGERS JA, KUNST PW, KOOLEN MG, WILLEMS LN, BURGERS JS et al. Pleural drainage and pleurodesis: implementation of guidelines in four hospitals. Eur Respir J 2008; 32: 1321-1327. http://dx.doi.org/10.1183/09031936.00165607
30. CHAKRA M, PUJOL JL, LAMY PJ, BOZONNAT MC, QUANTIN X et al. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer. J Thorac Oncol 2008; 3: 1119-1126. http://dx.doi.org/10.1097/JTO.0b013e318187464e
31. JELKMANN W Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem 2001; 47: 617-623.
32. HORMBREY E, GILLESPIE P, TURNER K, HAN C, ROBERTS A et al. A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: is the current literature meaningful. Clin Exp Metastasis 2002; 19: 651-663. http://dx.doi.org/10.1023/A:1021379811308
33. LEEUWENBERG JF, SMEETS EF, NEEFJES JJ, SHAFFER MA CINEK T et al. E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 1992; 77: 543-549.